Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Du bruger tilsyneladende en bredere skærm. Vil du gerne give denne side en bredere visningsoplevelse?

ExpreS2ion Biotechnologies – Presentation of Q2 interim report 2023

Af Michael FriisHead of Equities
ExpreS2ion Biotech Holding

Today, ExpreS2ion Biotechnologies released its Q2 2023 results and, more importantly, announced a review of its strategy, pipeline, and organization to materially extend the runway in a tight funding market. This includes, among others, a pause of the breast cancer candidate. With focus on the strategy announcement, the company’s CEO Bent Frandsen and CFO Keith Alexander presented the implications and potential effect of the strategy review, noting that this is in the first inning. 


ExpreS2ion Biotechnologies is a Danish biotechnology company, which focuses on the development of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral Drosophila S2 cells-based expression system.

 

HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 13.30 PM 28-04-2023.

Seneste videoer

Investor Day | Nov. 24, 2025
23.12.2025, 11.00 United Bankers
HCA Morgenbørs 23/12 - Flade futures og fokus på Novo Nordisk og Ørsted
23.12.2025, 09.27 Novo Nordisk
HCA Morgenbørs 22/12 - Positiv stemning i Asien og amerikanske futures i plus, mens Europa er fladt
22.12.2025, 09.28 GomSpace Group
HCA Morgenbørs 19/12 - Små fald i den europæiske åbning og fokus på flere danske aktier
19.12.2025, 09.25 Aquaporin
Talenom - Planned demerger and strategies of Talenom and Easor
18.12.2025, 11.00 Talenom
Vis alle videoer
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.